Drug Trial Radar · NCT07660094
Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)
Last checked: Nov 19, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
500
Planned (sponsor's estimate)
Start
Jun 15, 2026
Primary completion
Oct 22, 2031
Study completion Oct 22, 2031
Sponsor
- Lead sponsor
- Candel Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase III trial compares the effect of the combination of aglatimagene besadenovec and pembrolizumab versus standard of care docetaxel chemotherapy for the treatment of stage IV non-squamous, non-small cell lung cancer. Aglatimagene besadenovec is a replication-deficient adenoviral vector encoding the herpes simplex virus thymidine kinase (HSV-tk) gene. When combined with an oral prodrug (valacyclovir), injection of aglatimagene induces targeted tumor cell death and stimulates a systemic immune response. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out if giving aglatimagene with pembrolizumab is more effective at treating patients with stage IV non-squamous, non-small cell lung cancer than standard chemotherapy.
Conditions
- Non-squamous, Non-Small Cell Lung Cancer
Interventions
Aglatimagene BesadenovecBiological
via intratumoral injections into lung or lymph nodes at two timepoints
ValacyclovirDrug
Oral, for14 days following each aglatimagene besadenovec injection
PembrolizumabBiological
every 3 weeks (Q3W) or every 6 weeks (Q6W)
DocetaxelDrug
every 21 days with standard premedication
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall SurvivalTime frame: From date of randomization until date of death from any cause, assessed for a minimum of 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
New York, New York · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.